| Followers | 1 |
| Posts | 255 |
| Boards Moderated | 0 |
| Alias Born | 02/23/2024 |
Wednesday, March 13, 2024 2:32:38 PM
I'm highly hypothetically speaking but seems to me all these stocks places to chat or get information from, they all lie and are corrupt. They allow bashing on stocks that are being shorted, and they allow pumping of no name stocks or crypto to no end in sight. Everything online is literally created to either a get you to sell for a loss, or buy something at the top. Period. JAGX is going to prevail. Fuck these Internet criminals
Recent JAGX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 09:22:44 PM
- Jaguar Health Reports First Quarter 2026 Financials • ACCESS Newswire • 05/20/2026 08:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:36:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2026 08:06:56 PM
- Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference • ACCESS Newswire • 05/20/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 09:07:21 PM
- Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer • ACCESS Newswire • 05/19/2026 01:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/18/2026 07:06:14 PM
- Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule • ACCESS Newswire • 05/08/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 06:59:08 PM
- Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 05/06/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2026 12:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 09:09:41 PM
- Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 12:00:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 01:57:16 PM
- Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs • ACCESS Newswire • 04/29/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 01:10:06 PM
- Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split • ACCESS Newswire • 04/27/2026 01:00:00 PM
- Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) • ACCESS Newswire • 04/24/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/21/2026 12:22:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 11:35:12 AM
- Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders • ACCESS Newswire • 04/20/2026 08:15:00 PM
- Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs • ACCESS Newswire • 04/13/2026 12:30:00 PM
- Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates • ACCESS Newswire • 04/10/2026 12:15:00 AM
